PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$3.73B
1-Year Est. Return
133.76%
This Fund
S&P 500
1 Year Est. Return
+133.76%
AUM
$3.73B
AUM Growth
+$355M
(+11%)
Holding
42
Top Buys
| 1 | +$100M | |
| 2 | +$85.8M | |
| 3 | +$47.7M | |
| 4 |
Lexeo Therapeutics
LXEO
|
+$43.5M |
| 5 |
Scholar Rock
SRRK
|
+$39.5M |
Top Sells
| 1 | +$412M | |
| 2 | +$107M | |
| 3 | +$71.4M | |
| 4 |
Alkermes
ALKS
|
+$51.6M |
| 5 |
LENZ
LENZ Therapeutics
LENZ
|
+$50M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$7.77B
| $530M | 14.19% |
5,269,433
|
|
||
2
Revolution Medicines
RVMD
$19.4B
| $529M | 14.17% |
6,644,403
+421,112
|
|
||
3
Arcellx
ACLX
$6.6B
| $373M | 9.99% |
5,724,016
+1,075,000
|
|
||
4
Genmab
GMAB
$17B
| $217M | 5.81% |
7,039,834
+3,222,983
|
|
||
5
Tarsus Pharmaceuticals
TARS
$3.25B
| $210M | 5.62% |
2,562,154
-103,544
|
|
||
|
ABVX
6
Abivax
ABVX
$8.64B
| $191M | 5.12% |
1,417,473
-146,723
|
|
||
7
Olema Pharmaceuticals
OLMA
$1.85B
| $189M | 5.05% |
7,544,172
+750,000
|
|
||
8
Vaxcyte
PCVX
$8.47B
| $188M | 5.03% |
4,068,020
+283,265
|
|
||
|
CDTX
9
DELISTED
Cidara Therapeutics
CDTX
| $168M | 4.49% |
759,565
-201,599
|
|
||
10
Edgewise Therapeutics
EWTX
$3.11B
| $162M | 4.35% |
6,541,210
+371,079
|
|
||
|
11
Scholar Rock
SRRK
$4.82B
| $135M | 3.61% |
3,062,157
+1,052,412
|
|
||
12
UroGen Pharma
URGN
$903M
| $105M | 2.81% |
4,473,648
+257,564
|
|
||
13
Crinetics Pharmaceuticals
CRNX
$4.1B
| $103M | 2.76% |
2,210,774
-340,000
|
|
||
14
Apogee Therapeutics
APGE
$4.6B
| $84.8M | 2.27% |
1,123,243
-398,514
|
|
||
15
EyePoint Inc
EYPT
$1.49B
| $67.4M | 1.81% |
3,691,475
+1,686,110
|
|
||
16
Erasca
ERAS
$4.37B
| $52.7M | 1.41% |
14,159,095
+599,078
|
|
||
17
BridgeBio Pharma
BBIO
$12.4B
| $52.3M | 1.4% |
684,277
|
|
||
|
ORKA
18
Oruka Therapeutics
ORKA
$1.59B
| $51.8M | 1.39% |
+1,710,316
|
|
||
19
Spyre Therapeutics
SYRE
$3.18B
| $48.1M | 1.29% |
1,467,266
|
|
||
|
20
Lexeo Therapeutics
LXEO
$504M
| $47.3M | 1.27% |
+4,763,198
|
|
||
21
Viridian Therapeutics
VRDN
$2.78B
| $44.9M | 1.2% |
1,443,102
-1,166,251
|
|
||
22
Ocular Therapeutix
OCUL
$2.35B
| $35.6M | 0.95% |
2,935,284
-562,023
|
|
||
23
Terns Pharmaceuticals
TERN
$4.4B
| $32.7M | 0.88% |
+810,286
|
|
||
|
BBOT
24
BridgeBio Oncology
BBOT
$791M
| $28.3M | 0.76% |
2,261,749
+395,608
|
|
||
25
Vor Biopharma
VOR
$622M
| $22.9M | 0.61% |
+1,750,000
|
|